Literature DB >> 28274929

Hydrochlorothiazide treatment increases the abundance of the NaCl cotransporter in urinary extracellular vesicles of essential hypertensive patients.

Ganesh Pathare1, Omar A Z Tutakhel1, Mark C van der Wel2, Luke M Shelton1, Jaap Deinum3, Jacques W M Lenders3,4, Joost G J Hoenderop1, René J M Bindels5.   

Abstract

The thiazide-sensitive NaCl cotransporter (NCC), located apically in distal convoluted tubule epithelia, regulates the fine-tuning of renal sodium excretion. Three isoforms of NCC are generated through alternative splicing of the transcript, of which the third isoform has been the most extensively investigated in pathophysiological conditions. The aim of this study was to investigate the effect of different anti-hypertensive treatments on the abundance and phosphorylation of all three NCC isoforms in urinary extracellular vesicles (uEVs) of essential hypertensive patients. In uEVs isolated from patients (n = 23) before and after hydrochlorothiazide or valsartan treatment, the abundance and phosphorylation of the NCC isoforms was determined. Additionally, clinical biochemistry and blood pressure of the patients was assessed. Our results show that NCC detected in human uEVs has a glycosylated and oligomeric structure, comparable to NCC present in human kidney membrane fractions. Despite the inhibitory action of hydrochlorothiazide on NCC activity, immunoblot analysis of uEVs showed significantly increased abundance of NCC isoforms 1 and 2 (NCC1/2), total NCC (NCC1-3), and the phosphorylated form of total NCC (pNCC1-3-T55/T60) in essential hypertensive patients treated with hydrochlorothiazide but not with valsartan. This study highlights that NCC1/2, NCC1-3, and pNCC1-3-T55/T60 are upregulated by hydrochlorothiazide, and the increase in NCC abundance in uEVs of essential hypertensive patients correlates with the blood pressure response to hydrochlorothiazide.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  NaCl cotransporter; hypertension; kidney; thiazide diuretics; urinary extracellular vesicles

Mesh:

Substances:

Year:  2017        PMID: 28274929     DOI: 10.1152/ajprenal.00644.2016

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  6 in total

1.  Acute regulated expression of pendrin in human urinary exosomes.

Authors:  Ganesh Pathare; Nasser Dhayat; Nilufar Mohebbi; Carsten A Wagner; Lydie Cheval; Thomas J Neuhaus; Daniel G Fuster
Journal:  Pflugers Arch       Date:  2017-08-12       Impact factor: 3.657

Review 2.  Urinary Extracellular Vesicles as Biomarkers of Kidney Disease: From Diagnostics to Therapeutics.

Authors:  In O Sun; Lilach O Lerman
Journal:  Diagnostics (Basel)       Date:  2020-05-16

Review 3.  Role of the alternative splice variant of NCC in blood pressure control.

Authors:  Hila Wardak; Omar A Z Tutakhel; Jenny Van Der Wijst
Journal:  Channels (Austin)       Date:  2018       Impact factor: 2.581

4.  Does the composition of urinary extracellular vesicles reflect the abundance of renal Na+/phosphate transporters?

Authors:  Zsuzsi Radvanyi; Arezoo Daryadel; Eva Maria Pastor-Arroyo; Nati Hernando; Carsten Alexander Wagner
Journal:  Pflugers Arch       Date:  2022-09-08       Impact factor: 4.458

5.  Randomized Controlled Trial of Simple Salt Reduction Instructions by Physician for Patients with Type 2 Diabetes Consuming Excessive Salt.

Authors:  Chikako Oyabu; Emi Ushigome; Yuriko Ono; Ayaka Kobayashi; Yoshitaka Hashimoto; Ryosuke Sakai; Hiroya Iwase; Hiroshi Okada; Isao Yokota; Toru Tanaka; Michiaki Fukui
Journal:  Int J Environ Res Public Health       Date:  2021-06-28       Impact factor: 3.390

6.  NaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors and predicts thiazide sensitivity.

Authors:  Omar A Z Tutakhel; Arthur D Moes; Marco A Valdez-Flores; Marleen L A Kortenoeven; Mathijs V D Vrie; Sabina Jeleń; Robert A Fenton; Robert Zietse; Joost G J Hoenderop; Ewout J Hoorn; Luuk Hilbrands; René J M Bindels
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.